A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression
Trisha Suppes, Lauren B Marangell, Ira H Bernstein, Dorothy I Kelly, E Grace Fischer, Holly A Zboyan, Diane E Snow, Melissa Martinez, Rayan Al Jurdi, Geetha Shivakumar, Suresh Sureddi, Robert Gonzalez, Trisha Suppes, Lauren B Marangell, Ira H Bernstein, Dorothy I Kelly, E Grace Fischer, Holly A Zboyan, Diane E Snow, Melissa Martinez, Rayan Al Jurdi, Geetha Shivakumar, Suresh Sureddi, Robert Gonzalez
Abstract
Background: Treatment studies are lacking for patients with bipolar II disorder (BDII). The objective of this study was to compare lamotrigine (LTG) and lithium (Li) monotherapy for the treatment of BDII depression.
Methods: Patients with BDII acute depression were randomized to open-label monotherapy with LTG or Li, and evaluated by trained raters blinded to treatment. Patients were titrated to 200 mg/day of LTG over 8 weeks or at least 900 mg/day of Li over 2 weeks (serum level 0.6-1.2 mEq/L), and seen biweekly for 16 weeks. The primary outcome variable was change in the Hamilton Depression Rating Scale 17-item (Ham-D(17)), evaluated using mixed effects random regression.
Results: Both groups showed significant improvement from baseline to endpoint on the Ham-D(17) (p<0.0001), with no between group differences (p=0.95). Seventy-two percent of the population was rapid cycling by DSM-IV criteria. No differences in response were noted between rapid cyclers and non-rapid cyclers. Early termination for any cause was 42%. The Li group reported significantly more side effects, although drop-out due to side effects did not differ between groups.
Limitations: This study was limited by an open treatment design, a lack of placebo arm, and uneven treatment groups.
Conclusions: Lamotrigine and lithium were effective monotherapy for BDII depression, with comparable response and remission rates. Naturalistic design and lack of placebo limit conclusions, though patient history indicated long standing depression unlikely to be alleviated by time. Patients who received Li reported more side effects, but this did not appear to impact drop-out rates.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646842/bin/nihms79560f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646842/bin/nihms79560f2.jpg)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646842/bin/nihms79560f3a.jpg)
Figure 3
Figure 3a. Ham-D Item Differences…
Figure 3
Figure 3a. Ham-D Item Differences by group at week 16 For LTG, all…
- A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. Calabrese JR, et al. J Clin Psychiatry. 1999 Feb;60(2):79-88. doi: 10.4088/jcp.v60n0203. J Clin Psychiatry. 1999. PMID: 10084633 Clinical Trial.
- Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial.Amsterdam JD, Wang CH, Shwarz M, Shults J. Amsterdam JD, et al. J Affect Disord. 2009 Jan;112(1-3):219-30. doi: 10.1016/j.jad.2008.03.029. Epub 2008 May 16. J Affect Disord. 2009. PMID: 18486235 Clinical Trial.
- Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study.Wang Z, Gao K, Kemp DE, Chan PK, Serrano MB, Conroy C, Fang Y, Ganocy SJ, Findling RL, Calabrese JR. Wang Z, et al. Psychopharmacol Bull. 2010;43(4):5-21. Psychopharmacol Bull. 2010. PMID: 21240149 Free PMC article. Clinical Trial.
- [Antipsychotics in bipolar disorders].Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L. Vacheron-Trystram MN, et al. Encephale. 2004 Sep-Oct;30(5):417-24. doi: 10.1016/s0013-7006(04)95456-5. Encephale. 2004. PMID: 15627046 Review. French.
- ECNP consensus meeting. Bipolar depression. Nice, March 2007.Goodwin GM, Anderson I, Arango C, Bowden CL, Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU. Goodwin GM, et al. Eur Neuropsychopharmacol. 2008 Jul;18(7):535-49. doi: 10.1016/j.euroneuro.2008.03.003. Epub 2008 May 23. Eur Neuropsychopharmacol. 2008. PMID: 18501566 Review.
- Acute and Maintenance Treatment of Bipolar Depression.Erten E. Erten E. Noro Psikiyatr Ars. 2021 Sep 20;58(Suppl 1):S31-S40. doi: 10.29399/npa.27408. eCollection 2021. Noro Psikiyatr Ars. 2021. PMID: 34658633 Free PMC article. Review.
- Efficacy and safety of lamotrigine in the treatment of bipolar disorder across the lifespan: a systematic review.Besag FMC, Vasey MJ, Sharma AN, Lam ICH. Besag FMC, et al. Ther Adv Psychopharmacol. 2021 Oct 8;11:20451253211045870. doi: 10.1177/20451253211045870. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 34646439 Free PMC article. Review.
- Lamotrigine in the maintenance treatment of bipolar disorder.Hashimoto Y, Kotake K, Watanabe N, Fujiwara T, Sakamoto S. Hashimoto Y, et al. Cochrane Database Syst Rev. 2021 Sep 15;9(9):CD013575. doi: 10.1002/14651858.CD013575.pub2. Cochrane Database Syst Rev. 2021. PMID: 34523118 Free PMC article. Review.
- Lithium Treatment Over the Lifespan in Bipolar Disorders.Volkmann C, Bschor T, Köhler S. Volkmann C, et al. Front Psychiatry. 2020 May 7;11:377. doi: 10.3389/fpsyt.2020.00377. eCollection 2020. Front Psychiatry. 2020. PMID: 32457664 Free PMC article. Review.
- Development and pilot of a decision-aid for patients with bipolar II disorder and their families making decisions about treatment options to prevent relapse.Fisher A, Sharpe L, Anderson J, Manicavasagar V, Juraskova I. Fisher A, et al. PLoS One. 2018 Jul 10;13(7):e0200490. doi: 10.1371/journal.pone.0200490. eCollection 2018. PLoS One. 2018. PMID: 29990368 Free PMC article.
- Comparative Study
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Acute Disease
- Adolescent
- Adult
- Aged
- Ambulatory Care
- Anticonvulsants / adverse effects
- Anticonvulsants / therapeutic use*
- Bipolar Disorder / diagnosis
- Bipolar Disorder / drug therapy*
- Bipolar Disorder / psychology
- Diagnostic and Statistical Manual of Mental Disorders
- Drug Administration Schedule
- Female
- Humans
- Lamotrigine
- Lithium Compounds / adverse effects
- Lithium Compounds / therapeutic use*
- Male
- Middle Aged
- Patient Dropouts
- Psychiatric Status Rating Scales
- Severity of Illness Index
- Single-Blind Method
- Survival Analysis
- Treatment Outcome
- Triazines / adverse effects
- Triazines / therapeutic use*
- Anticonvulsants
- Lithium Compounds
- Triazines
- Lamotrigine
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2646842/bin/nihms79560f3b.jpg)
Source: PubMed